Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily KQT member 4 (KCNQ4), also known as voltage-gated potassium channel subunit Kv7.4, is a protein that forms part of a family of voltage-gated potassium channels essential for regulating neuronal excitability and maintaining membrane potential. It plays a critical role in regulating membrane potential in excitable cells, especially within sensory cells of the cochlea. Mutations in KCNQ4 cause nonsyndromic sensorineural deafness type 2 (DFNA2).
Retigabine and ML213 activate/open the channel, increasing potassium ion transport. Muscarinic acetylcholine receptor M1 activation inhibits the channel.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium Channel Subfamily KQT Member 4.